After hearing presentations from 43 speakers at the Fourth Global NASH Congress, the Surfing the NASH Tsunami team convenes one more time to debate how the diagnostics market will develop. With a profusion of options, physicians, payers and regulators will have decisions ahead. There is some disagreement on the year in which events will happen, but not on the basic pattern of market evolution.
TOPICS: cirrhosis, COVID-19, ELF, FIB-4, FibroScan, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, NAFLD, NASH, Siemens Healthineers, NIS-4, NASHnext, LabCorp,
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast